EUREX, a European Dermits Stock Exchange, announced on Wednesday that it will provide quantitative investment strategies to the futures market through a new partnership with a data and analysis specialist.
This initiative, which represents the last step in pushing Eurex to the “futures” of the markets, will be launched on October 27 with three futures for the QIS Employment Index based on indicators from Société Générale and Solacive.
The company explained that the new futures contracts aim to make the managed investment curricula systematically easily by converting the products that are traditionally circulated without a prescription (OTC) into a central format.
Eurex said that this step will reduce the complexity and costs associated with organizational frameworks such as the rules of exposed margins, with the door opened for a wide range of investors, including pension funds and asset managers.
“The futures of the new QIS reflect the ambition of Eurex in my future markets,” said Elena Marshaidan, a leader in the field of global products. “By providing a central and included an alternative to OTC’s bodies, we reduce costs and complexity with the expansion of the investor’s access.”
Premiab will provide index and analyzes data, including performance and risk standards, to ensure transparency. Each product will also be supported by a commercial participant sponsored to facilitate liquidity and effective pricing.
Adrian Giliot, CEO of Primalab, said the initiative “expanding access to QIS strategies for a wide range of institutional investors, creating new opportunities to diversify the portfolio.”
Eurex plans to expand the product group over time to include long lead strategies, targeted indicators of volatility, and the multiple assets approach, taking into account organizational approval.